Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin Sells 927 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Supernus Pharmaceuticals Stock Down 1.1 %

SUPN traded down $0.37 during trading hours on Monday, hitting $32.68. 729,077 shares of the company’s stock were exchanged, compared to its average volume of 443,779. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The stock’s 50-day moving average is $37.48 and its two-hundred day moving average is $35.38. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 30.54 and a beta of 0.90.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $57.00 to $36.00 in a report on Wednesday, February 19th.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Large investors have recently modified their holdings of the business. Pacer Advisors Inc. raised its holdings in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares in the last quarter. Woodline Partners LP increased its position in shares of Supernus Pharmaceuticals by 124.8% during the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock worth $15,326,000 after purchasing an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock worth $10,581,000 after purchasing an additional 208,552 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $6,847,000. Finally, Great Lakes Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $6,131,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.